Specifically, monoclonal antibodies targeting programmed cell death receptor 1/programmed cell death receptor ligand 1 (PD-1/PD-L1) have demonstrated enhanced survival rates in patients with lung cancer.5 This evidence concerns the gene CD274 and lung carcinoma.